nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Edema of lower extremities—Capecitabine—esophageal cancer	0.0366	0.066	CcSEcCtD
Solifenacin—Obstructive airways disorder—Methotrexate—esophageal cancer	0.0241	0.0434	CcSEcCtD
Solifenacin—Infection—Carboplatin—esophageal cancer	0.012	0.0217	CcSEcCtD
Solifenacin—Intestinal obstruction—Capecitabine—esophageal cancer	0.0108	0.0194	CcSEcCtD
Solifenacin—Torsade de pointes—Capecitabine—esophageal cancer	0.0105	0.0189	CcSEcCtD
Solifenacin—Ileus—Capecitabine—esophageal cancer	0.0104	0.0187	CcSEcCtD
Solifenacin—Hepatocellular injury—Cisplatin—esophageal cancer	0.00997	0.018	CcSEcCtD
Solifenacin—Hyperkalaemia—Cisplatin—esophageal cancer	0.00979	0.0176	CcSEcCtD
Solifenacin—Dysphonia—Capecitabine—esophageal cancer	0.00893	0.0161	CcSEcCtD
Solifenacin—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00814	0.0147	CcSEcCtD
Solifenacin—Liver disorder—Methotrexate—esophageal cancer	0.00803	0.0145	CcSEcCtD
Solifenacin—Dry eye—Capecitabine—esophageal cancer	0.00679	0.0122	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00565	0.0102	CcSEcCtD
Solifenacin—Atrial fibrillation—Capecitabine—esophageal cancer	0.00563	0.0101	CcSEcCtD
Solifenacin—Renal impairment—Capecitabine—esophageal cancer	0.00561	0.0101	CcSEcCtD
Solifenacin—Renal failure—Cisplatin—esophageal cancer	0.00548	0.00987	CcSEcCtD
Solifenacin—Cystitis noninfective—Methotrexate—esophageal cancer	0.00534	0.00963	CcSEcCtD
Solifenacin—Cystitis—Methotrexate—esophageal cancer	0.00528	0.00952	CcSEcCtD
Solifenacin—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00527	0.0095	CcSEcCtD
Solifenacin—Urinary retention—Capecitabine—esophageal cancer	0.00507	0.00914	CcSEcCtD
Solifenacin—Bladder pain—Methotrexate—esophageal cancer	0.00495	0.00891	CcSEcCtD
Solifenacin—Urinary tract disorder—Cisplatin—esophageal cancer	0.00494	0.00891	CcSEcCtD
Solifenacin—Liver function test abnormal—Capecitabine—esophageal cancer	0.00492	0.00887	CcSEcCtD
Solifenacin—Connective tissue disorder—Cisplatin—esophageal cancer	0.00492	0.00886	CcSEcCtD
Solifenacin—Urethral disorder—Cisplatin—esophageal cancer	0.00491	0.00884	CcSEcCtD
Solifenacin—Dry skin—Capecitabine—esophageal cancer	0.00489	0.00881	CcSEcCtD
Solifenacin—Abdominal pain upper—Capecitabine—esophageal cancer	0.00487	0.00878	CcSEcCtD
Solifenacin—Muscular weakness—Capecitabine—esophageal cancer	0.0047	0.00847	CcSEcCtD
Solifenacin—Eye disorder—Cisplatin—esophageal cancer	0.00468	0.00843	CcSEcCtD
Solifenacin—Cardiac disorder—Cisplatin—esophageal cancer	0.00465	0.00837	CcSEcCtD
Solifenacin—Influenza—Capecitabine—esophageal cancer	0.00461	0.0083	CcSEcCtD
Solifenacin—Immune system disorder—Cisplatin—esophageal cancer	0.00452	0.00815	CcSEcCtD
Solifenacin—Mediastinal disorder—Cisplatin—esophageal cancer	0.00451	0.00813	CcSEcCtD
Solifenacin—Malnutrition—Cisplatin—esophageal cancer	0.00436	0.00785	CcSEcCtD
Solifenacin—Dysuria—Capecitabine—esophageal cancer	0.00431	0.00777	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00421	0.00758	CcSEcCtD
Solifenacin—Infestation—Capecitabine—esophageal cancer	0.00411	0.0074	CcSEcCtD
Solifenacin—Infestation NOS—Capecitabine—esophageal cancer	0.00411	0.0074	CcSEcCtD
Solifenacin—Vision blurred—Cisplatin—esophageal cancer	0.00411	0.0074	CcSEcCtD
Solifenacin—Depression—Capecitabine—esophageal cancer	0.0041	0.00738	CcSEcCtD
Solifenacin—Renal failure—Capecitabine—esophageal cancer	0.00404	0.00728	CcSEcCtD
Solifenacin—Urinary tract infection—Capecitabine—esophageal cancer	0.004	0.0072	CcSEcCtD
Solifenacin—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00389	0.007	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00368	0.00664	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—esophageal cancer	0.00367	0.0066	CcSEcCtD
Solifenacin—Pharyngitis—Capecitabine—esophageal cancer	0.00366	0.0066	CcSEcCtD
Solifenacin—Urinary tract disorder—Capecitabine—esophageal cancer	0.00364	0.00656	CcSEcCtD
Solifenacin—Oedema peripheral—Capecitabine—esophageal cancer	0.00364	0.00655	CcSEcCtD
Solifenacin—Connective tissue disorder—Capecitabine—esophageal cancer	0.00363	0.00653	CcSEcCtD
Solifenacin—Urethral disorder—Capecitabine—esophageal cancer	0.00362	0.00652	CcSEcCtD
Solifenacin—Anaphylactic shock—Cisplatin—esophageal cancer	0.00356	0.00641	CcSEcCtD
Solifenacin—Infection—Cisplatin—esophageal cancer	0.00353	0.00636	CcSEcCtD
Solifenacin—Erythema multiforme—Capecitabine—esophageal cancer	0.00349	0.00629	CcSEcCtD
Solifenacin—Nervous system disorder—Cisplatin—esophageal cancer	0.00349	0.00628	CcSEcCtD
Solifenacin—Tachycardia—Cisplatin—esophageal cancer	0.00347	0.00625	CcSEcCtD
Solifenacin—Skin disorder—Cisplatin—esophageal cancer	0.00345	0.00622	CcSEcCtD
Solifenacin—Eye disorder—Capecitabine—esophageal cancer	0.00345	0.00621	CcSEcCtD
Solifenacin—Cardiac disorder—Capecitabine—esophageal cancer	0.00342	0.00617	CcSEcCtD
Solifenacin—Angiopathy—Capecitabine—esophageal cancer	0.00335	0.00603	CcSEcCtD
Solifenacin—Immune system disorder—Capecitabine—esophageal cancer	0.00333	0.006	CcSEcCtD
Solifenacin—Mediastinal disorder—Capecitabine—esophageal cancer	0.00333	0.00599	CcSEcCtD
Solifenacin—Mental disorder—Capecitabine—esophageal cancer	0.00323	0.00582	CcSEcCtD
Solifenacin—Malnutrition—Capecitabine—esophageal cancer	0.00321	0.00579	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—esophageal cancer	0.00321	0.00578	CcSEcCtD
Solifenacin—Dysgeusia—Capecitabine—esophageal cancer	0.00315	0.00567	CcSEcCtD
Solifenacin—Decreased appetite—Cisplatin—esophageal cancer	0.00309	0.00557	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00307	0.00553	CcSEcCtD
Solifenacin—Infestation—Methotrexate—esophageal cancer	0.00306	0.00551	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—esophageal cancer	0.00306	0.00551	CcSEcCtD
Solifenacin—Depression—Methotrexate—esophageal cancer	0.00305	0.0055	CcSEcCtD
Solifenacin—Vision blurred—Capecitabine—esophageal cancer	0.00303	0.00545	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—esophageal cancer	0.00301	0.00542	CcSEcCtD
Solifenacin—Feeling abnormal—Cisplatin—esophageal cancer	0.00293	0.00528	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00289	0.00521	CcSEcCtD
Solifenacin—Palpitations—Capecitabine—esophageal cancer	0.00284	0.00511	CcSEcCtD
Solifenacin—Cough—Capecitabine—esophageal cancer	0.0028	0.00505	CcSEcCtD
Solifenacin—Hypertension—Capecitabine—esophageal cancer	0.00277	0.005	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—esophageal cancer	0.00273	0.00491	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00272	0.00489	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—esophageal cancer	0.00271	0.00489	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—esophageal cancer	0.00269	0.00485	CcSEcCtD
Solifenacin—Dry mouth—Capecitabine—esophageal cancer	0.00267	0.00482	CcSEcCtD
Solifenacin—Confusional state—Capecitabine—esophageal cancer	0.00264	0.00476	CcSEcCtD
Solifenacin—Hypersensitivity—Cisplatin—esophageal cancer	0.00262	0.00472	CcSEcCtD
Solifenacin—Infection—Capecitabine—esophageal cancer	0.0026	0.00469	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—esophageal cancer	0.0026	0.00468	CcSEcCtD
Solifenacin—Nervous system disorder—Capecitabine—esophageal cancer	0.00257	0.00463	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—esophageal cancer	0.00257	0.00462	CcSEcCtD
Solifenacin—Tachycardia—Capecitabine—esophageal cancer	0.00256	0.00461	CcSEcCtD
Solifenacin—Asthenia—Cisplatin—esophageal cancer	0.00255	0.0046	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—esophageal cancer	0.00255	0.00459	CcSEcCtD
Solifenacin—Skin disorder—Capecitabine—esophageal cancer	0.00255	0.00459	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—esophageal cancer	0.00249	0.00449	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—esophageal cancer	0.00248	0.00447	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—esophageal cancer	0.00248	0.00446	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—esophageal cancer	0.00241	0.00434	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—esophageal cancer	0.00239	0.00431	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—esophageal cancer	0.00234	0.00422	CcSEcCtD
Solifenacin—Dyspepsia—Capecitabine—esophageal cancer	0.00231	0.00416	CcSEcCtD
Solifenacin—Decreased appetite—Capecitabine—esophageal cancer	0.00228	0.00411	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00226	0.00408	CcSEcCtD
Solifenacin—Vomiting—Cisplatin—esophageal cancer	0.00226	0.00407	CcSEcCtD
Solifenacin—Fatigue—Capecitabine—esophageal cancer	0.00226	0.00407	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—esophageal cancer	0.00225	0.00406	CcSEcCtD
Solifenacin—Rash—Cisplatin—esophageal cancer	0.00224	0.00404	CcSEcCtD
Solifenacin—Constipation—Capecitabine—esophageal cancer	0.00224	0.00404	CcSEcCtD
Solifenacin—Dermatitis—Cisplatin—esophageal cancer	0.00224	0.00404	CcSEcCtD
Solifenacin—Feeling abnormal—Capecitabine—esophageal cancer	0.00216	0.00389	CcSEcCtD
Solifenacin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00214	0.00386	CcSEcCtD
Solifenacin—Nausea—Cisplatin—esophageal cancer	0.00211	0.00381	CcSEcCtD
Solifenacin—Cough—Methotrexate—esophageal cancer	0.00209	0.00376	CcSEcCtD
Solifenacin—Urticaria—Capecitabine—esophageal cancer	0.00208	0.00375	CcSEcCtD
Solifenacin—Abdominal pain—Capecitabine—esophageal cancer	0.00207	0.00373	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00202	0.00364	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—esophageal cancer	0.00197	0.00354	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—esophageal cancer	0.00195	0.00352	CcSEcCtD
Solifenacin—Infection—Methotrexate—esophageal cancer	0.00194	0.00349	CcSEcCtD
Solifenacin—Hypersensitivity—Capecitabine—esophageal cancer	0.00193	0.00348	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—esophageal cancer	0.00191	0.00345	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—esophageal cancer	0.0019	0.00341	CcSEcCtD
Solifenacin—Asthenia—Capecitabine—esophageal cancer	0.00188	0.00339	CcSEcCtD
Solifenacin—Pruritus—Capecitabine—esophageal cancer	0.00185	0.00334	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—esophageal cancer	0.00174	0.00313	CcSEcCtD
Solifenacin—Dizziness—Capecitabine—esophageal cancer	0.00173	0.00312	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—esophageal cancer	0.00172	0.00309	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—esophageal cancer	0.0017	0.00306	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00168	0.00304	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—esophageal cancer	0.00168	0.00303	CcSEcCtD
Solifenacin—Vomiting—Capecitabine—esophageal cancer	0.00167	0.003	CcSEcCtD
Solifenacin—Rash—Capecitabine—esophageal cancer	0.00165	0.00298	CcSEcCtD
Solifenacin—Dermatitis—Capecitabine—esophageal cancer	0.00165	0.00297	CcSEcCtD
Solifenacin—Headache—Capecitabine—esophageal cancer	0.00164	0.00296	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—esophageal cancer	0.00161	0.0029	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.0016	0.00287	CcSEcCtD
Solifenacin—Nausea—Capecitabine—esophageal cancer	0.00156	0.00281	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—esophageal cancer	0.00155	0.00279	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—esophageal cancer	0.00154	0.00278	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—esophageal cancer	0.00144	0.00259	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—esophageal cancer	0.0014	0.00252	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—esophageal cancer	0.00138	0.00249	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—esophageal cancer	0.00129	0.00232	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—esophageal cancer	0.00124	0.00224	CcSEcCtD
Solifenacin—Rash—Methotrexate—esophageal cancer	0.00123	0.00222	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—esophageal cancer	0.00123	0.00221	CcSEcCtD
Solifenacin—Headache—Methotrexate—esophageal cancer	0.00122	0.0022	CcSEcCtD
Solifenacin—Nausea—Methotrexate—esophageal cancer	0.00116	0.00209	CcSEcCtD
Solifenacin—CHRM1—Signaling by GPCR—CXCL2—esophageal cancer	0.000326	0.000732	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCL2—esophageal cancer	0.000325	0.00073	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—SST—esophageal cancer	0.000324	0.000729	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—GNG7—esophageal cancer	0.000324	0.000728	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—SST—esophageal cancer	0.000323	0.000727	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP26A1—esophageal cancer	0.000322	0.000723	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCL2—esophageal cancer	0.000321	0.000723	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—SST—esophageal cancer	0.00032	0.00072	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—GHRL—esophageal cancer	0.000316	0.00071	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—GHRL—esophageal cancer	0.000315	0.000708	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALOX15—esophageal cancer	0.000314	0.000705	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—GHRL—esophageal cancer	0.000312	0.000701	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—GNG7—esophageal cancer	0.00031	0.000697	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000306	0.000687	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CSNK1A1—esophageal cancer	0.000305	0.000685	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—XIAP—esophageal cancer	0.000303	0.000682	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ANXA1—esophageal cancer	0.000303	0.000681	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ANXA1—esophageal cancer	0.000302	0.000678	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000302	0.000678	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GSTO1—esophageal cancer	0.000299	0.000673	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—TPI1—esophageal cancer	0.000299	0.000673	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ANXA1—esophageal cancer	0.000299	0.000672	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—SST—esophageal cancer	0.000294	0.000662	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—SST—esophageal cancer	0.000294	0.00066	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—SST—esophageal cancer	0.000291	0.000653	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—XIAP—esophageal cancer	0.000291	0.000653	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00029	0.000651	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000289	0.000649	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—GHRL—esophageal cancer	0.000287	0.000645	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CTNNA1—esophageal cancer	0.000287	0.000645	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALDOB—esophageal cancer	0.000287	0.000645	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—GHRL—esophageal cancer	0.000286	0.000643	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PFN1—esophageal cancer	0.000286	0.000643	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL2—esophageal cancer	0.000285	0.000641	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PFN1—esophageal cancer	0.000285	0.000641	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—GHRL—esophageal cancer	0.000283	0.000637	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PFN1—esophageal cancer	0.000282	0.000634	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000281	0.000632	CbGpPWpGaD
Solifenacin—CHRM3—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.00028	0.00063	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GAPDH—esophageal cancer	0.000276	0.000621	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CTNNA1—esophageal cancer	0.000275	0.000618	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CRABP1—esophageal cancer	0.000274	0.000615	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL2—esophageal cancer	0.000273	0.000614	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PSME1—esophageal cancer	0.000266	0.000599	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PSME2—esophageal cancer	0.000266	0.000599	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ANXA1—esophageal cancer	0.000265	0.000596	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GNG7—esophageal cancer	0.00026	0.000585	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SST—esophageal cancer	0.000258	0.00058	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ELMO1—esophageal cancer	0.000257	0.000577	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—TP53—esophageal cancer	0.000257	0.000577	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ELMO1—esophageal cancer	0.000256	0.000575	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PSME1—esophageal cancer	0.000255	0.000574	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PSME2—esophageal cancer	0.000255	0.000574	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ANXA1—esophageal cancer	0.000254	0.000571	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ELMO1—esophageal cancer	0.000253	0.00057	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000251	0.000565	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—GHRL—esophageal cancer	0.000251	0.000565	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOTCH3—esophageal cancer	0.000251	0.000565	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKAP13—esophageal cancer	0.000251	0.000564	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000251	0.000564	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKAP13—esophageal cancer	0.00025	0.000562	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKAP13—esophageal cancer	0.000248	0.000557	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—FBXW7—esophageal cancer	0.000247	0.000556	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SST—esophageal cancer	0.000247	0.000555	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALDH2—esophageal cancer	0.000244	0.000548	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOTCH3—esophageal cancer	0.000241	0.000541	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—GHRL—esophageal cancer	0.000241	0.000541	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—FBXW7—esophageal cancer	0.000237	0.000532	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GSTT1—esophageal cancer	0.000232	0.000521	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000232	0.000521	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000231	0.000519	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PDE4D—esophageal cancer	0.00023	0.000516	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP2A6—esophageal cancer	0.000229	0.000515	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PDE4D—esophageal cancer	0.000229	0.000514	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000229	0.000514	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PDE4D—esophageal cancer	0.000227	0.000509	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOTCH2—esophageal cancer	0.000226	0.000507	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GNG7—esophageal cancer	0.000218	0.000491	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GNG7—esophageal cancer	0.000218	0.000489	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ENO1—esophageal cancer	0.000217	0.000489	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS1—esophageal cancer	0.000217	0.000489	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOTCH2—esophageal cancer	0.000216	0.000485	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GNG7—esophageal cancer	0.000216	0.000484	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PSME2—esophageal cancer	0.000214	0.000482	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PSME1—esophageal cancer	0.000214	0.000482	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000213	0.00048	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000213	0.00048	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—XIAP—esophageal cancer	0.000205	0.00046	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—XIAP—esophageal cancer	0.000204	0.000458	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—XIAP—esophageal cancer	0.000202	0.000454	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFBR2—esophageal cancer	0.0002	0.00045	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000193	0.000435	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CTNNA1—esophageal cancer	0.000193	0.000434	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000192	0.000432	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL2—esophageal cancer	0.000192	0.000431	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFBR2—esophageal cancer	0.000192	0.000431	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CTNNA1—esophageal cancer	0.000191	0.000429	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL2—esophageal cancer	0.00019	0.000427	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SMAD4—esophageal cancer	0.000189	0.000426	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP1B1—esophageal cancer	0.000185	0.000416	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000182	0.000408	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CA1—esophageal cancer	0.000182	0.000408	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SMAD4—esophageal cancer	0.000181	0.000408	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PSME2—esophageal cancer	0.00018	0.000404	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PSME1—esophageal cancer	0.00018	0.000404	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PSME2—esophageal cancer	0.000179	0.000403	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PSME1—esophageal cancer	0.000179	0.000403	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	0.000179	0.000402	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ANXA1—esophageal cancer	0.000178	0.000401	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PSME1—esophageal cancer	0.000177	0.000399	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PSME2—esophageal cancer	0.000177	0.000399	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ANXA1—esophageal cancer	0.000177	0.000397	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SST—esophageal cancer	0.000174	0.000391	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP19A1—esophageal cancer	0.000174	0.000391	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SST—esophageal cancer	0.000173	0.00039	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SST—esophageal cancer	0.000172	0.000386	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	0.00017	0.000381	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GHRL—esophageal cancer	0.00017	0.000381	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GHRL—esophageal cancer	0.000169	0.00038	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOTCH3—esophageal cancer	0.000169	0.00038	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GHRL—esophageal cancer	0.000167	0.000376	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOTCH3—esophageal cancer	0.000167	0.000376	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	0.000167	0.000375	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FBXW7—esophageal cancer	0.000166	0.000374	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CA2—esophageal cancer	0.000166	0.000373	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FBXW7—esophageal cancer	0.000165	0.00037	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—HMOX1—esophageal cancer	0.000159	0.000356	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HIF1A—esophageal cancer	0.000155	0.000348	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000154	0.000347	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000154	0.000347	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ABCB1—esophageal cancer	0.000152	0.000342	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	0.000152	0.000342	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOTCH2—esophageal cancer	0.000152	0.000341	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOTCH2—esophageal cancer	0.00015	0.000337	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HIF1A—esophageal cancer	0.000148	0.000334	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KDR—esophageal cancer	0.000148	0.000333	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KDR—esophageal cancer	0.000142	0.000319	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOTCH1—esophageal cancer	0.00014	0.000314	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000135	0.000304	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	0.000135	0.000303	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFBR2—esophageal cancer	0.000134	0.000302	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOTCH1—esophageal cancer	0.000134	0.0003	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFBR2—esophageal cancer	0.000133	0.000299	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000129	0.000291	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	0.000128	0.000287	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SMAD4—esophageal cancer	0.000127	0.000286	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CREBBP—esophageal cancer	0.000127	0.000284	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SMAD4—esophageal cancer	0.000126	0.000283	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000126	0.000283	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—EGFR—esophageal cancer	0.000124	0.00028	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000123	0.000276	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CREBBP—esophageal cancer	0.000121	0.000272	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—EGFR—esophageal cancer	0.000119	0.000268	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000119	0.000267	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000117	0.000263	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000117	0.000263	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000114	0.000256	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOS3—esophageal cancer	0.000113	0.000255	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000112	0.000252	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOS3—esophageal cancer	0.000109	0.000244	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.000108	0.000243	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—PIK3CA—esophageal cancer	0.000108	0.000243	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000107	0.00024	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ERBB2—esophageal cancer	0.000106	0.000238	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	0.000104	0.000235	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	0.000104	0.000234	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—PIK3CA—esophageal cancer	0.000103	0.000232	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	0.000103	0.000232	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000102	0.000229	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CREBBP—esophageal cancer	0.000102	0.000229	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ERBB2—esophageal cancer	0.000101	0.000228	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KDR—esophageal cancer	9.99e-05	0.000225	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KDR—esophageal cancer	9.96e-05	0.000224	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KDR—esophageal cancer	9.86e-05	0.000222	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALDH2—esophageal cancer	9.53e-05	0.000214	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	9.41e-05	0.000212	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	9.38e-05	0.000211	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCND1—esophageal cancer	9.36e-05	0.00021	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	9.29e-05	0.000209	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—NOS3—esophageal cancer	9.11e-05	0.000205	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTT1—esophageal cancer	9.07e-05	0.000204	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	9.06e-05	0.000204	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCND1—esophageal cancer	8.97e-05	0.000202	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.96e-05	0.000202	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	8.67e-05	0.000195	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EP300—esophageal cancer	8.62e-05	0.000194	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	8.53e-05	0.000192	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	8.51e-05	0.000191	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS1—esophageal cancer	8.5e-05	0.000191	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ENO1—esophageal cancer	8.5e-05	0.000191	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	8.42e-05	0.000189	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	8.39e-05	0.000189	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PSME1—esophageal cancer	8.37e-05	0.000188	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PSME2—esophageal cancer	8.37e-05	0.000188	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	8.36e-05	0.000188	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—esophageal cancer	8.33e-05	0.000187	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	8.28e-05	0.000186	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EP300—esophageal cancer	8.25e-05	0.000186	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.01e-05	0.00018	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	7.99e-05	0.00018	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	7.91e-05	0.000178	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOS3—esophageal cancer	7.64e-05	0.000172	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOS3—esophageal cancer	7.62e-05	0.000171	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOS3—esophageal cancer	7.54e-05	0.00017	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—esophageal cancer	7.51e-05	0.000169	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—esophageal cancer	7.35e-05	0.000165	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	7.28e-05	0.000164	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	7.25e-05	0.000163	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1B1—esophageal cancer	7.23e-05	0.000162	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—esophageal cancer	7.19e-05	0.000162	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	7.18e-05	0.000161	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	7.15e-05	0.000161	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	7.12e-05	0.00016	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	7.05e-05	0.000159	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—esophageal cancer	7.04e-05	0.000158	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—EP300—esophageal cancer	6.93e-05	0.000156	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.79e-05	0.000153	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	6.38e-05	0.000143	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCND1—esophageal cancer	6.31e-05	0.000142	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCND1—esophageal cancer	6.29e-05	0.000141	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCND1—esophageal cancer	6.23e-05	0.00014	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMOX1—esophageal cancer	6.2e-05	0.000139	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TP53—esophageal cancer	6.17e-05	0.000139	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	6.11e-05	0.000137	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	6.11e-05	0.000137	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	6.09e-05	0.000137	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	6.03e-05	0.000136	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.95e-05	0.000134	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TP53—esophageal cancer	5.91e-05	0.000133	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EP300—esophageal cancer	5.81e-05	0.000131	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EP300—esophageal cancer	5.79e-05	0.00013	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EP300—esophageal cancer	5.74e-05	0.000129	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CA—esophageal cancer	5.13e-05	0.000115	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—esophageal cancer	5.06e-05	0.000114	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—esophageal cancer	5.05e-05	0.000113	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—esophageal cancer	5e-05	0.000112	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—esophageal cancer	4.95e-05	0.000111	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—esophageal cancer	4.94e-05	0.000111	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—esophageal cancer	4.89e-05	0.00011	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	4.3e-05	9.66e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	4.29e-05	9.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	4.24e-05	9.54e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TP53—esophageal cancer	4.16e-05	9.35e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TP53—esophageal cancer	4.15e-05	9.32e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TP53—esophageal cancer	4.11e-05	9.23e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.98e-05	8.94e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NOS3—esophageal cancer	3.56e-05	8e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.26e-05	7.32e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—EP300—esophageal cancer	2.71e-05	6.09e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2e-05	4.5e-05	CbGpPWpGaD
